SCPX (Scorpius Holdings) Cyclically Adjusted PS Ratio: 0.00 (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Scorpius Holdings Cyclically Adjusted PS Ratio?

Scorpius Holdings SCPX -45.45% Cyclically Adjusted PS Ratio is 0.00 as of Jul. 16, 2026. The stock has 7 warning signs investors should review. Among 539 Biotechnology companies, Scorpius Holdings ranks worse than 185528.57% on this metric.

As of today (2026-07-16), Scorpius Holdings's current share price is $0.0012. Scorpius Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2025 was $223.76. Scorpius Holdings's Cyclically Adjusted PS Ratio for today is 0.00.

The historical rank and industry rank for Scorpius Holdings's Cyclically Adjusted PS Ratio or its related term are showing as below:

During the past years, Scorpius Holdings's highest Cyclically Adjusted PS Ratio was 1.92. The lowest was 0.01. And the median was 0.49.

SCPX's Cyclically Adjusted PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 5.82
* Ranked among companies with meaningful Cyclically Adjusted PS Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Scorpius Holdings's adjusted revenue per share data for the three months ended in Sep. 2025 was $0.004. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $223.76 for the trailing ten years ended in Sep. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Scorpius Holdings  (OTCPK:SCPX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Scorpius Holdings Cyclically Adjusted PS Ratio Related Terms


Scorpius Holdings Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Scorpius Holdings's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scorpius Holdings Cyclically Adjusted PS Ratio Chart

Scorpius Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.56 0.34 0.00

Scorpius Holdings Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

SCPX vs CARM, CYTOF, CNBX: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Scorpius Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scorpius Holdings Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scorpius Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Scorpius Holdings's Cyclically Adjusted PS Ratio falls into.



Scorpius Holdings Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Scorpius Holdings's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.0012/223.76
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scorpius Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2025 is calculated as:

For example, Scorpius Holdings's adjusted Revenue per Share data for the three months ended in Sep. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Sep. 2025 (Change)*Current CPI (Sep. 2025)
=0.004/324.8000*324.8000
=0.004

Current CPI (Sep. 2025) = 324.8000.

Scorpius Holdings Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201512 0.000 236.525 0.000
201603 0.000 238.132 0.000
201606 0.000 241.018 0.000
201609 220.000 241.428 295.972
201612 60.500 241.432 81.391
201703 12.000 243.801 15.987
201706 0.000 244.955 0.000
201709 157.000 246.819 206.603
201712 204.667 246.524 269.653
201803 251.000 249.554 326.682
201806 103.909 251.989 133.933
201809 108.235 252.439 139.260
201812 89.478 251.233 115.679
201903 29.208 254.202 37.320
201906 14.250 256.143 18.070
201909 0.250 256.759 0.316
201912 83.292 256.974 105.276
202003 22.000 258.115 27.684
202006 9.413 257.797 11.859
202009 8.252 260.280 10.298
202012 5.336 260.474 6.654
202103 4.455 264.877 5.463
202106 3.643 271.696 4.355
202109 0.000 274.310 0.000
202112 0.000 278.802 0.000
202203 1.656 287.504 1.871
202206 0.398 296.311 0.436
202209 0.461 296.808 0.504
202212 0.625 296.797 0.684
202303 5.892 301.836 6.340
202306 5.062 305.109 5.389
202309 5.562 307.789 5.869
202312 37.292 306.746 39.487
202403 24.922 312.332 25.917
202406 2.310 314.175 2.388
202409 0.131 315.301 0.135
202412 0.421 315.605 0.433
202503 0.023 319.799 0.023
202506 0.005 322.561 0.005
202509 0.004 324.800 0.004

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

What does a Cyclically Adjusted PS Ratio of 0.00 mean?
Scorpius Holdings (SCPX) has a Cyclically Adjusted PS Ratio of 0.00 as of Jul. 16, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Scorpius Holdings and its competitors. Over the past decade, Scorpius Holdings' Cyclically Adjusted PS Ratio has ranged from 0.01 to 1.92. According to the industry distribution chart, Scorpius Holdings ranks #999999 out of 539 companies in the Biotechnology industry.
Is Scorpius Holdings' Cyclically Adjusted PS Ratio too high?
Scorpius Holdings' current Cyclically Adjusted PS Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 1.92. Based on the distribution chart, Scorpius Holdings ranks #999999 out of 539 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Scorpius Holdings' Cyclically Adjusted PS Ratio compare to CARM and CYTOF?
According to the Biotechnology industry distribution chart, Scorpius Holdings ranks #999999 out of 539 companies for Cyclically Adjusted PS Ratio. This places Scorpius Holdings in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 5.82. Historically, Scorpius Holdings' own Cyclically Adjusted PS Ratio has ranged from 0.01 to 1.92 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 5.82, based on 539 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Scorpius Holdings and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 5.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scorpius Holdings's current Cyclically Adjusted PS Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scorpius Holdings stock overvalued right now?
Based on GuruFocus' analysis, Scorpius Holdings (SCPX) is currently considered Possible Value Trap. The stock's GF Value™ is $0.14, compared to a current price of $0.00 — trading 99.1% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Scorpius Holdings (SCPX), the current Cyclically Adjusted PS Ratio is 0.00 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scorpius Holdings Business Description

Address 1305 East Houston Street, San Antonio, TX, USA, 27560
Scorpius Holdings Inc is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond. It offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state of the art facilities.